Trung Huynh
Stock Analyst at UBS
(4.55)
# 253
Out of 4,966 analysts
52
Total ratings
62.86%
Success rate
21.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $2.80 | +792.86% | 3 | Aug 15, 2025 | |
| INSM Insmed | Maintains: Buy | $133 → $140 | $136.10 | +2.87% | 7 | Aug 13, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,050 → $895 | $732.58 | +22.17% | 9 | Aug 8, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $287.71 | +10.18% | 6 | Aug 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $560 → $584 | $580.70 | +0.57% | 4 | Jul 11, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $22.06 | +72.26% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $24.76 | +0.97% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $47.18 | +14.46% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.45 | +382.76% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $3.71 | +250.40% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $177.17 | -1.22% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $84.12 | +49.79% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $210.40 | -19.20% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.97 | - | 1 | Mar 23, 2021 |
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $2.80
Upside: +792.86%
Insmed
Aug 13, 2025
Maintains: Buy
Price Target: $133 → $140
Current: $136.10
Upside: +2.87%
Eli Lilly and Company
Aug 8, 2025
Maintains: Buy
Price Target: $1,050 → $895
Current: $732.58
Upside: +22.17%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $287.71
Upside: +10.18%
Regeneron Pharmaceuticals
Jul 11, 2025
Maintains: Neutral
Price Target: $560 → $584
Current: $580.70
Upside: +0.57%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $22.06
Upside: +72.26%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $24.76
Upside: +0.97%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $47.18
Upside: +14.46%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.45
Upside: +382.76%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $3.71
Upside: +250.40%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $177.17
Upside: -1.22%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $84.12
Upside: +49.79%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $210.40
Upside: -19.20%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.97
Upside: -